Ilorasertib
Phase 2Terminated 0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Cancers
Conditions
Advanced Cancers
Trial Timeline
Aug 5, 2016 → May 12, 2022
NCT ID
NCT02478320About Ilorasertib
Ilorasertib is a phase 2 stage product being developed by AbbVie for Advanced Cancers. The current trial status is terminated. This product is registered under clinical trial identifier NCT02478320. Target conditions include Advanced Cancers.
What happened to similar drugs?
16 of 20 similar drugs in Advanced Cancers were approved
Approved (16) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02478320 | Phase 2 | Terminated |
Competing Products
20 competing products in Advanced Cancers